Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Assessment of Safety, Efficacy, Pharmacokinetics and Immunogenicity of BI 695501 in Patients With Rheumatoid Arthritis (RA): an Open-label Extension Trial for Patients Who Have Completed Trial 1297.2 and Are Eligible for Long-term Treatment With Adalimumab

NCT02640612 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02640612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02640612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Assessment of Safety, Efficacy, Pharmacokinetics and Immunogenicity of BI 695501 in Patients With Rheumatoid Arthritis (RA): an Open-label Extension Trial for Patients Who Have Completed Trial 1297.2 and Are Eligible for Long-term Treatment With Adalimumab
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
January 22, 2016
Completion date
November 1, 2017
Enrollment
430 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid